PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
30.26%
Net income growth similar to AGEN's 33.33%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
-2.10%
Both reduce yoy D&A, with AGEN at -1.01%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Both cut yoy SBC, with AGEN at -1.17%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-263.50%
Both reduce yoy usage, with AGEN at -228.64%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.17%
Both reduce yoy usage, with AGEN at -141.64%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-397.71%
Negative yoy while AGEN is 603.29%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.50%
Some CFO growth while AGEN is negative at -14.38%. John Neff would note a short-term liquidity lead over the competitor.
-802.66%
Both yoy lines negative, with AGEN at -25.86%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.56%
Both yoy lines negative, with AGEN at -8.64%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-100.00%
Negative yoy issuance while AGEN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.